Overview

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of Apatinib for patients with Recurrent or Recurrent High-grade Glioma.
Phase:
Phase 2
Details
Lead Sponsor:
West China Hospital
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib